BioStock: Medivir continues to accelerate development with fostrox

Medivir’s recently published Annual Report for 2023 focuses primarily on the drug candidate fostrox. Clinical data shows improved efficacy in patients with advanced primary liver cancer when the drug is combined with Lenvima. The company continues to accelerate clinical development with the aim of establishing fostrox as the first approved treatment for second-line liver cancer. BioStock reached out to the company’s CEO Jens Lindberg for a comment on the past year, and to learn of his expectations for the rest of 2024.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2024/04/medivir-continues-to-accelerate-development-with-fostrox/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/